. New creatine transporter assay and identification of distinct creatine transporter isoforms in muscle. Am J Physiol Endocrinol Metab 283: E390-E401, 2002. First published February 26, 2002 10.1152/ajpendo.00428.2001.-Despite the pivotal role of creatine (Cr) and phosphocreatine (PCr) in muscle metabolism, relatively little is known about sarcolemmal creatine transport, creatine transporter (CRT) isoforms, and subcellular localization of the CRT proteins. To be able to quantify creatine transport across the sarcolemma, we have developed a new in vitro assay using rat sarcolemmal giant vesicles. The rat giant sarcolemmal vesicle assay reveals the presence of a specific high-affinity and saturable transport system for Cr in the sarcolemma (Michaelis-Menten constant 52.4 Ϯ 9.4 M and maximal velocity value 17.3 Ϯ 3.1 pmol ⅐ min Ϫ1 ⅐ mg vesicle protein Ϫ1 ), which cotransports Cr into skeletal muscle together with Na ϩ and Cl Ϫ ions. The regulation of Cr transport in giant vesicles by substrates, analogs, and inhibitors, as well as by phorbol 12-myristate 13-acetate and insulin, was studied. Two antibodies raised against COOH-and NH 2-terminal synthetic peptides of CRT sequences both recognize two major polypeptides on Western blots with apparent molecular masses of 70 and 55 kDa, respectively. The highest CRT expression occurs in heart, brain, and kidney, and although creatine kinase is absent in liver cells, CRT is also found in this tissue. Surprisingly, immunofluorescence staining of cultured adult rat heart cardiomyocytes with specific anti-CRT antibodies, as well as cell fractionation and cell surface biotinylation studies, revealed that only a minor CRT species with an intermediate molecular mass of ϳ58 kDa is present in the sarcolemma, whereas the previously identified major CRT-related protein species of 70 and 55 kDa are specifically located in mitochondria. Our studies indicate that mitochondria may represent a major compartment of CRT localization, thus providing a new aspect to the current debate about the existence and whereabouts of intracellular Cr and PCr compartments that have been inferred from [ 14 C]PCr/Cr measurements in vivo as well as from recent in vivo NMR studies.
plasma membrane giant vesicles; sarcolemma; mitochondria; subcellular compartmentation of creatine; bioenergetics CLINICAL APPLICATIONS OF CREATINE (Cr) supplementation have recently attracted considerable attention, and a series of intriguing new discoveries about potential therapeutic effects of Cr have been made. Cr analogs have been proven to be prospective anticancer agents that act synergistically with currently used chemotherapeutics (3, 25, (35) (36) (37) 53) , and beneficial effects of Cr supplementation have been reported for congestive heart failure (17, 26) , atherosclerotic heart disease (8, 12, 44) , neuromuscular disease (38, 64, 62) , stroke, and neurodegenerative disease (7, 30, 39) , as well as in the treatment of muscular weakness in gyrate atrophy (22, 56, 68) , as a therapeutic aid for Duchenne muscular dystrophy (45, 48, 75) and mitochondrial myopathies (31) (see Refs. 65, 77 for review). Apparently, many skeletal muscle and heart diseases are associated with disturbances in Cr metabolism, either as a primary defect or secondary to other metabolic derangements that critically influence skeletal muscle performance. The reduced intramuscular Cr and phosphocreatine (PCr) content that is observed in such diseases seems to be related to a decreased expression and/or accumulation of the Cr transporter (CRT) that is responsible for Cr uptake and storage in these cell types (43, 63) . Muscle diseases with impaired ion regulation such as Duchenne muscular dystrophy, where the ionic balance, especially Ca 2ϩ homeostasis, is disturbed, may contribute to the dysfunction of the CRT, which relies on a sodium chloride gradient to cotransport Cr across the plasma membrane (21) .
CRT has been mapped to the human chromosome Xq28 (13, 27) , a locus that has been linked to several hereditary neuromuscular disorders such as Barth syndrome and infantile cardiomyopathy (1, 4) . Because of the major role of Cr in muscular physiology, we consider the CRT a candidate gene that may be involved or is affected in these diseases. Indeed, very recently, a CRT gene defect has been described that leads to a Cr deficiency syndrome with developmental delay, hypotonia, and severe delay in both speech and expressive language function (51) .
Given the importance of Cr supplementation in pathology, it seems very surprising that there is no in vitro assay available to study possible functional impairments of the CRT in such diseases. The CRT assay described here, as well as the anti-CRT antibodies characterized in this study, may prove useful for functional testing and clinical screening of such patients, respectively.
The expression of the CRT in several tissues has been studied earlier with the use of specific anti-CRT antibodies (20, 41, 43, 66) and has revealed different forms of CRT, expressed in various tissues, that are most likely derived from alternative splicing (20) . The finding of two different mRNAs in these tissues (21, 23, 42, 52, 55) has supported this assumption.
Here, using our anti-CRT antibodies generated against both NH 2 -and COOH-terminal peptides, we provide evidence for the existence of independent forms of CRT species in skeletal muscle. In combination with in situ biotinylation and immunofluorescence methods, a minor CRT species present in the sarcolemma and two major, yet unknown, CRT species specifically located in mitochondria are revealed.
EXPERIMENTAL PROCEDURES
Materials. Nycodenz, collagenase (type VII), ␤-guanidinopropionic acid (␤-GPA), guanidinoacetic acid (GAA), Cr, cyclocreatine, creatinine, taurine, PCr, ouabain, gramicidin A, phorbol 12-myristate 13-acetate (PMA), 4␣-phorbol 12,13-didecanoate, anti-protease cocktail, avidin, and streptavidin beads were from Sigma (Buchs, Switzerland); Phenylmethylsulfonyl fluoride (PMSF) was from SERVA (Heidelberg, Germany); [4- 14 C]Cr was from American Radiolabeled Chemicals; [ 3 H]mannitol was from NEN Life Science (The Netherlands); Hybond-P polyvinylidene difluoride (PVDF) membrane, Percoll, and ECL-Plus chemiluminescence detection kit were from Amersham Biosciences (Dü bendorf, Switzerland). Secondary antibodies goat anti-mouse Cy5 and goat anti-rabbit Cy3 were from Amersham Biosciences, goat antirabbit FITC and monkey anti-sheep FITC were from Pierce, and goat anti-rabbit horseradish peroxidase (HRP) was from Nordic (Tilburg, The Netherlands). Primary antibodies: monoclonal mouse anti-voltage-dependent anion channel (VDAC) was from Calbiochem (USA), COOH-and NH2-terminal polyclonal CRT antipeptide antibodies were produced as described (20) , polyclonal adenine nucleotide translocase (ANT) antipeptide antibodies were produced as described (50) , mouse anti-cytochrome c oxidase subunit IV (COX) was from Molecular Probes, polyclonal sheep anti-CRT antibodies were produced by ANAWA (Wangen, Switzerland), and their specificity against CRT protein has been established (unpublished observations), polyclonal anti-human sarcomeric mitochondrial creatine kinase (Mis-CK) antibody (32) and polyclonal anti-human cytosolic muscle-type (M)-CK antibody (54) have been described.
Cr transport assay into giant sarcolemmal vesicles. Preparation and characterization of giant sarcolemmal vesicles from rat skeletal muscles (gastrocnemius, soleus, and quadriceps femoris) were performed as described (34, 46) . The purity of the vesicle preparation was additionally supported by Western blotting with the use of antibodies against the Na ϩ -K ϩ -ATPase and the mitochondrial markers VDAC and ANT (data not shown). The protein concentration of the vesicle preparation was adjusted to 5 mg/ml. Cr transport was measured at 37°C and started by adding 10 l of the vesicle preparation to 90 l of transport buffer. The transport buffer contained 10 M [
14 C]Cr, 1 Ci/ml [ 3 H]mannitol, 100 M Cr, 134 mM NaCl, 2 mM MgCl 2, 2 mM Na2HPO4, and 10 mM Tris ⅐ HCl, pH 7.4. To determine the ion dependence, 134 mM NaCl was exchanged either by 134 mM KCl, LiCl, NaF, or Na-acetate or Na-citrate or 88 mM Na 2SO4. Inhibition of Cr transport was measured in NaCl transport buffer with final concentrations of 4 mM of glucose, fructose, or maltose or 1 mM each of either ouabain, ␤-GPA, GAA, PCr, creatinine, cyclocreatine, taurine, or caffeine or 1 M gramicidin A or 10 M of either PMA or 4␣-phorbol 12,13-didecanoate as 100-fold stock solutions in ethanol. In the experiments designed to study the effects of insulin on vesicle transport of Cr, anesthetized rats were injected with 10 U of human insulin (Novo Nordisk) in a tail vein 20 min before muscles were removed for the preparation of giant vesicles, as described (46) . The transport assay was stopped by adding 1 ml of ice-cold transport buffer (lacking isotopes and Cr), centrifugation at 16,000 g for 1 min, and removal of the supernatant. The pellet was solubilized in 100 l of 1% SDS and counted in 4 ml of the scintillation cocktail Ultima Gold XR (Packard) in a Packard 1500 Tri-Carb liquid scintillation counter. Doubleisotope measurement settings were 0-18 eV for the 3 H isotope and 18-256 eV for the 14 C isotope. Protein extracts from rat tissues. Wistar rats (male, 3-4 mo of age) were anesthetized with diethyl ether and killed by cervical dislocation. Tissues were freed from fat and connective tissue, washed in MSH buffer (10 mM HEPES-HCl, pH 7.4, 220 mM mannitol, 70 mM sucrose) and homogenized in 5 vol of MSH at 0°C. Brain, kidney, testis, and nonperfused liver were homogenized with a glass Teflon potter, whereas intestine, lung, and muscle tissues were homogenized with a Polytron mixer. The homogenate was supplemented to 5% SDS and heated at 75°C for 15 min with shaking. After centrifugation at 16,000 g for 10 min, the supernatant was used for analysis. Protein determination was performed with bicinchoninic acid (BCA) protein assay reagent from Pierce. SDS-PAGE minigels were carried out according to standard procedures with 30 g protein/lane. Immunoblots were performed using COOH-or NH2-terminal anti-CRT antibody.
Tissue extracts and isolation of mitochondria from rat soleus. Wistar rats (male, 3-4 mo of age) were anesthetized with diethyl ether and killed by cervical dislocation. Soleus muscle was immediately homogenized by a Polytron mixer in 40 ml of HEPES-sucrose buffer containing 250 mM sucrose, 10 mM HEPES-KOH, pH 7.4, 0.5% BSA (essentially fat free) and 1 mM EDTA. The homogenate was centrifuged for 10 min at 700 g to remove heavy debris such as platelets and nuclei. An aliquot from the supernatant was taken as tissue extract. The supernatant was centrifuged for 10 min at 7,000 g. The supernatant was taken as cytoplasm, and the pellet containing mitochondria was resuspended in 60 ml of 250 mM sucrose, 10 mM HEPES-KOH, pH 7.4, 100 M EGTA, and 25% Percoll and centrifuged for 35 min at 100,000 g. Percoll fractions containing highly enriched mitochondria were washed twice with 250 mM sucrose, 10 mM HEPES-KOH, pH 7.4, and 100 M EGTA at 7,000 g for 10 min.
Washed mitochondria were then recovered from the pellet and resuspended in 200 l of buffer. Protein determination was performed with BCA protein assay reagent. SDS-PAGE minigels were carried out according to standard procedures with 10 g protein/lane. Immunoblots were performed using COOH-terminal anti-CRT antibody, polyclonal anti-human Mi s-CK antibody (as mitochondrial marker), and polyclonal anti-human M-CK antibody (as cytosolic marker).
Succinate dehydrogenase enzyme assay. The specific succinate dehydrogenase (SDH) activity of mitochondrial preparations was measured indirectly via the increase in the absorption of reduced cytochrome c at 550 nm (⑀ ϭ 19 mM Ϫ1 / cm). Samples (10 l) were incubated in 1 ml of 50 mM Na 2HPO4, 50 mM NaH2PO4, pH 7.4, 100 M cytochrome c, 1 mM KCN, and 2.5 mM succinate as described (5) .
Cell cultures for immunofluorescence studies. For adult rat cardiomyocytes (ARC), ventricular cardiac myocytes of adult female rats (2 mo of age) were isolated by retrograde perfusion of hearts according to an established method (14) . Culture dishes were coated with 0.1% gelatin. After isolation, ARC were cultured in M-199 medium containing 20% fetal calf serum, 20 mM Cr monohydrate, and 100 U/ml penicillinstreptomycin. For growth inhibition of fibroblasts and other proliferation-competent cells, 10 M cytosine arabinoside was added to the medium.
Isolation of myocytes for cell surface labeling. Mouse cardiac myocytes were isolated according to established methods (47) . Briefly, hearts from six control C57BL/10 mice (male, 6 mo of age) weighing ϳ30 g were excised under pentobarbitone anesthesia (140 mg/ml) and immediately arrested in perfusion buffer (see below). Hearts were perfused for 5 min by retrograde coronary perfusion with a calcium-free buffer containing (in mM) 134 NaCl, 5.4 KCl, 0.3 NaH 2PO4 ⅐ 2H2O, 1.0 MgCl2, 5.0 Na-acetate, 5.0 Na-pyruvate, 11 glucose, 5.0 HEPES, 20 taurine, and 10 Cr and 10 mU/ml insulin, pH 7.25. This was followed by 10 min with perfusion buffer supplemented with collagenase (1 mg/ml), protease (0.1 mg/ ml), and CaCl2 (80 M). An increased coronary flow at 5-7 min indicated a breakdown of the coronary bed, at which point the coronary flow rate was reduced to 1 drop/s. Subsequently, the ventricles were dissected and placed in a stirred enzyme incubation solution (calcium-free buffer containing 1 mg/ml collagenase, 0.1 mg/ml protease, 10 mg/ml albumin, 100 M CaCl2) for 10 min at 37°C. The supernatant was filtered through a nylon gauze mesh and made up to 10 ml with wash solution (10 mg/ml albumin, 500 M CaCl2). Cells were centrifuged for 1 min at 20-30 g and resuspended again in 10 ml of wash solution.
Cell surface biotinylation. Cell surface expression of the CRT was determined using the membrane-impermeable biotinylation reagent sulfo-NHS-LC-biotin (10, 61) . Isolated myocytes were washed three times with ice-cold PBS and then incubated with PBS containing 1.0 mg/ml sulfo-NHS-LC-biotin for 30-45 min with constant shaking at 4°C. After labeling, the cells were washed three times in ice-cold PBS containing glycine (15 mM) to quench the residual sulfo-NHS-LC-biotin. Subsequently, cells were solubilized by resuspension in solubilization buffer [containing 150 mM NaCl, 20 mM HEPES, 2 mM PMSF, 1 mM EDTA, 0.1% Triton X-100, and anti-protease cocktail (1:100 dilution)] and gentle shaking for ϳ1 h. The extracts were clarified by centrifugation at 13,000 g for 5 min at 4°C. A portion of the lysate was taken for immediate incubation with streptavidin beads, whereas the remaining lysate was kept for protein determination and immunoblotting of the total cell extract.
Streptavidin beads (100 l) were washed three times in wash buffer (containing 150 mM NaCl and 10 mM Tris, pH 7.0) by rapid centrifugation. Lysate (100 g protein) was added to the beads, incubated on ice, and rotated/shaken for 2 h. Samples were then washed by rapid centrifugation with wash buffer plus anti-proteases. To elute the biotinylated protein from the beads, 80 l of urea buffer (containing 9 M urea, 2% SDS, and 100 mM Tris, pH 6.8) plus antiproteases were added and incubated (with constant shaking) for 30 min at 95°C. Finally, tubes were centrifuged at 13,000 g, and the supernatant representing the captured biotinylated protein was collected and subsequently analyzed by Western blotting.
Erythrocyte preparation. Fresh heparinized blood from mice (male, 6 mo of age) was taken and immediately spun at 13,000 g for 10 min. The supernatant was discarded, and red cells were washed by rapid centrifugation three times with isosmotic buffer (MOPS-buffered saline). The supernatant was discarded, and ϳ250 l of red blood cells were resuspended in solubilization buffer (see Cell surface biotinylation) and incubated with shaking for 30 min at 4°C. The suspension was again spun at 13,000 g and the supernatant taken and kept at Ϫ70°C before use.
Western blotting. Total cell extracts (cardiac myocytes and erythrocytes at 20 and 100 g protein/lane, respectively) and captured biotinylated proteins (100 g protein/lane) were separated on a 10% SDS-polyacrylamide gel and subsequently transferred onto a Hybond-P PVDF membrane. The membrane was blocked with 5% fat-free milk powder in TBS-T buffer (137 mM NaCl, 2.6 mM KCl, 25 mM Tris ⅐ HCl, 0.1% Tween-20, pH 7.4) for 1 h at room temperature (followed by 1 h in TBS supplemented with avidin at a concentration of 20 g/ml for the biotinylation experiments). After a 1-h washing, membranes were incubated with a 1:3,000 dilution of the anti-CRT COOH-terminal antibody for 1 h at room temperature. After a washing with TBS-T buffer, the blot was incubated with a 1:5,000 dilution of the HRP-conjugated anti-rabbit antibody. The immunoreactive bands were visualized using the ECL-Plus chemiluminescence detection kit.
Immunofluorescence of cultured adult rat myocytes and soleus sections. Freshly excised rat soleus muscle was fixed in PBS containing 3% paraformaldehyde. Tissues were embedded in paraffin and cut to 10-m slices with a microtome. Paraffin was removed with xylole, and the slices were washed with 70% ethanol and stored in PBS. Cell cultures and sections of rat soleus were rinsed with PBS and then fixed with PBS and 0.3% PFA for 15 min at room temperature and washed three times for 5 min with PBS. After permeabilization with PBS and 0.3% Triton X-100 for 20 min at room temperature and washing for 3 ϫ 5 min with PBS, the samples were blocked with PBS containing 4% milk powder for 1 h at room temperature. Finally, the samples were incubated with primary antibody at 4°C overnight. Antibody dilutions in PBS containing 4% milk powder were 1:200 for polyclonal rabbit anti-CRT COOH-or NH2-terminal antibody, 1:100 for polyclonal sheep anti-CRT, 1:100 for polyclonal rabbit anti-ANT, 1:200 mouse anti-COX, and 1:50 for monoclonal mouse anti-VDAC. Controls were performed in parallel experiments with the use of the corresponding sera of nonimmunized animals, where no specific signal could be discerned (not shown). The cells were washed three times for 5 min with PBS followed by incubation with the conjugate dilutions in PBS for 2 h at room temperature (goat antirabbit FITC 1:200, goat anti-mouse Cy3 1:1,000, monkey anti-sheep FITC 1:200, goat anti-rabbit TRITC 1:200, goat anti-mouse Cy5 1:200). After three PBS washing steps of 5 min each, cells were embedded in antifading medium containing 30 mM Tris ⅐ HCl, pH 9.5, 70% (vol/vol) glycerol, and 240 mM N-propyl gallate and covered with coverslips. Sections were analyzed with a confocal microscope Zeiss Axio-phot fluorescence microscope, a Bio-Rad MRC-600 confocal scanner unit, and a Silicon Graphics Iris 4D/25 workstation. Images were recorded with oil immersion objectives using a Zeiss Neofluar ϫ40/1.3 objective or a Zeiss Neofluar ϫ63/1.3 objective. The system was equipped with an argon-krypton mixed-gas laser. Image processing was with a Silicon Graphics workstation using Imaris (Bitplane) software.
RESULTS

Characterization of Cr transport in sarcolemmal giant vesicles.
The time course of Cr uptake into giant sarcolemmal vesicles (Fig. 1A) showed linear uptake until 5 min, whereupon leveling off occurred. Uptake in relation to concentration follows saturation kinetics with an apparent Michaelis-Menten constant (K m ) and maximal velocity (V max ) for Cr transport of 52.4 Ϯ 9.4 M and 17.3 Ϯ 3.1 pmol ⅐ min Ϫ1 ⅐ mg Ϫ1 vesicle protein, respectively (Fig. 1, B and C) .
Cr transport into skeletal muscle was dependent on an extracellular Na ϩ and Cl Ϫ gradient. As shown in Fig. 2 , replacement of the NaCl gradient by a potassium or lithium chloride gradient in the extravesicular medium completely abolished Cr transport. Likewise, the presence of 1 M gramicidin A, a powerful Na ϩ ionophore that completely collapses the Na ϩ gradient between extra vs. intravesicular space (69) , stopped the Cr transport due to Na ϩ influx into the vesicles (Table 1 ). In contrast, ouabain, a selective inhibitor of the Na ϩ -K ϩ -ATPase pump (11, 57) , the enzyme that establishes the sodium gradient in intact cells in vivo and balances the influx and efflux of sodium and potassium cations, was unable to affect Cr uptake (Table 1) .
In addition, the effects of changes in the external concentrations of anions on Cr uptake into skeletal muscle were examined. Figure 2 also shows that Cr transport considerably diminished when uptake buffers containing anions other than Cl Ϫ were used. Exchange of the NaCl gradient by an Na-fluoride, -citrate, -acetate, or -sulfate gradient led to a significant loss of Cr transport activity. Thus Cr uptake into skeletal muscle appears to be strictly dependent on an NaCl gradient.
To analyze the specificity of the sarcolemmal CRT for its substrate Cr, we examined the effects of structurally related compounds and Cr analogs for their ability to inhibit and/or compete with the CRT activity. Figure  3 shows that ␤-GPA, a well known competitive inhibitor of Cr uptake (16) , had the most prominent inhibitory effect on Cr transport into skeletal muscle. The presence of 1 mM ␤-GPA in the extravesicular buffer was sufficient to decrease Cr uptake to ϳ25% of control rates. The Cr analog cyclocreatine, at 1 mM in the transport buffer, led to an ϳ50% decrease in Cr uptake, indicating that it competes for the CRT and is itself taken up by the giant sarcolemmal vesicles. Other structurally related compounds such as creatinine, the degradation product of Cr, and taurine did not inhibit Cr uptake to any significant level, whereas GAA, the precursor molecule of Cr, decreased Cr uptake by ϳ15%. Remarkably, the phosphorylated form of Cr was not recognized as a substrate of the CRT and did not interfere with Cr uptake (Fig. 3) . We further studied the effect of caffeine, which was shown to somehow attenuate the ergogenic effects of Cr (67) on Cr uptake, but we were not able to show direct effects of this drug on Cr uptake at concentrations of 1 mM in the transport buffer and after preincubation of the vesicle preparation for 20 min at 37°C (Table 1) .
Active and inactive phorbol esters, which were used in other studies to single out the regulation of CRT activity by protein kinase C (PKC)-dependent phosphorylation (9, 42), were not able to influence Cr transport activity in giant sarcolemmal vesicles when present in the transport buffer and after preincubation of the vesicle preparation with these compounds for 20 min at 37°C at 10 M concentration (Table 1) . Also the carbohydrates glucose, fructose, and maltose could not change Cr uptake into giant vesicles by its presence in the transport buffer (Table 1) . Likewise insulin, after intravenous injection into rats and subsequent preparation of giant vesicles, did not result in significant alterations of Cr transport compared with vesicle preparations from control animals ( Table 1) .
Expression of CRT polypeptide species in different tissues. To find out whether Cr content correlates with CRT expression in various tissues, we generated specific antipeptide antibodies directed against the COOHand NH 2 -terminal regions of the cDNA-derived CRT sequence (20) . Neither region shows any sequence homology to other members of the Na ϩ -and Cl Ϫ -dependent neurotransmitter transporter family or to any other proteins in a homology search in the EMBL database. On immunoblots, with the use of these antisera, two major protein bands with an apparent electrophoretic mobility of 70 and 55 kDa were consistently recognized in all tissues tested ( Fig. 4A ; only the COOH-terminal antibody shown). Protein expression was most prominent in excitable and metabolically active tissues such as brain and heart, as well as in kidney, and also in liver, the principal organ where the final step of Cr synthesis takes place. Lower levels of CRT expression were observed in white glycolytic skeletal muscle (gastrocnemius), lung, testis, and intestine. Values are means Ϯ SE. Creatine (Cr) uptake assays were performed for 5 min at 100 M Cr in uptake buffers containing the compounds indicated or after additional preincubation (*) for 20 min at 37°C at the indicated concentration. Insulin was intravenously injected into rats 20 min before muscles were removed for vesicle preparation. Amount of Cr uptake is expressed as pmol/mg total vesicle protein. Mean values are from 4 individual experiments, in each of which Cr transport was measured in duplicate. Differential subcellular compartmentation of CRT polypeptide species. CRT protein is expected to be highly enriched in purified plasma membrane vesicles. However, anti-CRT immunoblots of giant vesicles (Fig.  4B, lane V) showed only minor expression of an ϳ58-kDa protein taking a total protein extract from rat skeletal muscle (Fig. 4B, lane T) as reference. The immunoreactive signal of the 55-and 70-kDa proteins was almost absent, whereas a rather weak 58-kDa polypeptide appeared that was enriched in these giant vesicle preparations (Fig. 4B, lane V) . On the other hand, a preparation of purified mitochondria from rat skeletal muscle showed an enrichment of the 55-and 70-kDa CRT immunoreactive bands compared with the total extract (Fig. 4B, lane M) .
This result was confirmed by cell fractionation of rat soleus muscle and purification of mitochondria in Percoll density gradients (Fig. 5) . The purity of the mitochondrial fraction was carefully checked with cytosolic and mitochondrial marker antibodies anti-MCK and anti-Mi s -CK, respectively, showing a high enrichment of CRT proteins in the mitochondrial preparation (Fig.  5, A and B) . Furthermore, the purity of the mitochondrial preparations was controlled by measuring enzyme activities of complex II (SDH) and complex III (cytochrome c reductase) indirectly via increasing absorption of reduced cytochrome c.
The relative surface abundance of the CRT from cardiac myocytes was determined using a surface biotinylation study, which proves that the third ϳ58-kDa polypeptide band, which is seen in the giant sarcolemmal vesicles, binds to the streptavidin beads (Fig. 6A,  lanes 1 and 3) and consequently appears to be located on the cell surface. In contrast, the 55-and 70-kDa CRT immunoreactive bands seen in the total extract (Fig. 6A, lanes 2 and 4) and in the total extracts of Fig.  4A of all tissues tested could not be discerned by cell surface labeling.
In addition, erythrocytes from mouse, which were shown to possess an active NaCl-dependent CRT (2) but do not contain mitochondria, were probed for CRT expression. We found that erythrocytes from mouse express only a single ϳ58-kDa polypeptide form of the CRT (Fig. 6B) with an apparently similar electrophoretic mobility as that found in the captured biotinylated protein and in the giant sarcolemmal vesicle preparations. There was no sign of the presence of polypeptides at 55 or 70 kDa.
Indirect immunofluorescence labeling of cultured adult rat cardiomyocytes with anti-CRT antibodies clearly shows co-staining of anti-CRT signal with mitochondrial marker antibodies directed against ANT or VDAC (Fig. 7, A-D) . This result was also obtained by immunofluorescence studies on cross sections of rat soleus muscle by use of anti-CRT antibodies, with anti-COX antibodies as mitochondrial marker (Fig. 7,  E-H) . Because the immunofluorescence signal from the subsarcolemmal mitochondria is very strong, the weak plasma membrane staining in soleus cross sections overlapping with sarcolemma-associated mitochondria often cannot be clearly discerned.
The Cr transport studies presented here for determining the kinetics of CRT were routinely done with sarcolemma vesicles isolated from anesthetized rats kept on a normal rat feed diet. However, to address the question of whether CRT expression in the plasma membrane could possibly be altered by the extracellular availability of Cr, we were looking for a possible increase in CRT expression in the plasma membrane of Fig. 5 . Identification of CRT in rat soleus mitochondria. Ten micrograms each of total tissue extract (total) of rat soleus muscle, together with the corresponding cytoplasmic fractions (cytopl) and mitochondria (mito), isolated from adult rat soleus muscle, were electroblotted, stained with 0.2% Ponceau red in 3% trichloroacetic acid solution (A) and probed with polyclonal rabbit anti-CRT antibody and a polyclonal anti-human sarcomeric mitochondrial creatine kinase (Mis-CK), which is located in the mitochondrial intermembrane and intercristae membrane space and is also concentrated in contact sites (thus used as mitochondrial enzyme marker), as well as with polyclonal anti-human cytosolic muscle-type (M)-CK antibody (as cytosolic enzyme marker). Shown are the extracts from two different animals (A and B) . Both the 55-and 70-kDa bands were stained equally with anti-COOH-(shown here) and anti-NH2-terminal antibodies (not shown). To check the mitochondrial preparations, the enzyme activities of complex II [succinate dehydrogenase (SDH)] and complex III (cytochrome c reductase) were measured indirectly via increasing absorption of reduced cytochrome c. Complex IV [cytochrome c oxidase (COX)] was blocked with 1 mM KCN to keep cytochrome c reduced. Electrons were fed in with 2.5 mM succinate. Soleus muscle fractions from 3 animals were measured in triplicate. The means of the total extract and the mitochondrial fraction are statistically significantly different (P Ͻ 0.0005, one-way ANOVA; C).
ARC cultured in either Cr-deficient or Cr-supplemented medium for Յ10 days. Even under Cr-deficient conditions, where ARC start to display abnormally long and enlarged mitochondria with paracrystalline intramitochondrial inclusions (15), we did not observe an increase in sarcolemmal immunofluorescence signal in such ARC (not shown).
DISCUSSION
A new in vitro assay: Cr transport into giant sarcolemmal vesicles. Many skeletal muscle, heart, and neuromuscular diseases are characterized by a reduced intracellular Cr and PCr content, and Cr supplementation, which increases Cr content in skeletal muscle Յ20%, has been reported to be beneficial in the treatment of these diseases (77) . In addition, the CRT gene has been mapped to the human chromosome Xq28 (13, 27) , a locus that has been linked to several neuromuscular diseases (1, 4) . Thus the sarcolemmal CRT, which regulates intracellular Cr content and is responsible for maintaining the extremely high concentration gradient across the plasma membrane, is a likely candidate gene that may be functionally affected by, or is even responsible for, some of these diseases, as has been already demonstrated in patients with Cr deficiency syndrome (51) . However, research to study a possible involvement of the CRT in such diseases, i.e., due to mutations leading to the expression of a nonfunctional protein, has been hampered by the lack of a suitable assay system that would allow the comparison of the CRT parameters in healthy and pathological subjects. Because the preparation of giant sarcolemmal Areas of co-localization of CRT immunofluorescence with ANT signal are specified in yellow (D). Phase contrast image of cross sections of rat soleus (E) and indirect anti-CRT immunofluorescence staining (F) co-stained for the mitochondrial marker protein COX (G). Areas of co-localization of CRT immunofluorescence with mitochondria are specified in yellow (H). Note, staining shown here was with anti-COOH-terminal anti-CRT antibody, but the same results were obtained using anti-NH2-terminal anti-CRT antibodies (not shown).
vesicles from human biopsies has already been studied in the case of the lactate transporter (28, 29) and GLUT4 (34), the Cr transport assay described here may provide a novel tool to investigate a possible involvement of the CRT in such diseases.
Skeletal muscle CRT from rat, present in the giant sarcolemmal vesicles, clearly showed a specific, saturable, high-affinity, and NaCl-dependent uptake of Cr, which is best inhibited by the Cr analogs ␤-GPA and cyclocreatine. The apparent K m of 52 M, as measured here, is well in agreement with that of earlier studies (77) that investigated the kinetic parameters of the CRT and thus seems to reflect the physiologically very low Cr plasma levels of 25-50 M (70, 77).
As shown in Fig. 3 , the phosphorylated form of Cr is not a substrate for the CRT. Consequently, the intracellular formation of PCr by the PCr/CK system, as well as the strict discrimination between Cr and PCr by the CRT, leads to entrapment of PCr inside the cell, since PCr escapes equilibration. This thermodynamically facilitates further Cr uptake and helps maintain the enormous total Cr concentration gradient (600-to 1,000-fold) across the plasma membrane. The V max of Cr uptake into giant sarcolemmal vesicles is somewhat difficult to compare with previous studies of the CRT, with either intact muscle or myogenic cells, since these values are given relative to different measures of tissue mass, intracellular water volume, tissue dry weight, or mass of protein. When the V max is compared with other plasma membrane transporters such as GLUT4 (46) or lactate transporter (29) , which were investigated using sarcolemmal giant vesicles, Cr uptake seems slow. In view of the physiological function of a sarcolemmal CRT, that is, to transport as much Cr into the muscle cells as has been lost by the slow and constant nonenzymatic degradation of Cr to creatinine, Cr turnover rates are expected to be low and steady with no need of temporarily elevated Cr transport capacity.
On the other hand, Cr transport might be upregulated, i.e., after food ingestion. It was reported that subjects ingesting Cr together with carbohydrates attained far higher muscle Cr levels (18, 19, 49) , and studies investigating the effects of insulin in vivo on plasma and muscle Cr accumulation could demonstrate that insulin can enhance muscle Cr accumulation in humans but only when present at physiologically high or supraphysiological concentrations (60) . Therefore, we examined the response to various carbohydrates as well as to insulin of Cr uptake into giant sarcolemmal vesicles (Table 1) but were unable to detect significant changes in Cr transport activity in vitro, indicating that these observations are due to secondary or regulatory effects taking place in vivo and that Cr transport is apparently not directly regulated by insulin or the presence of carbohydrates, at least under the conditions used.
The amino acid sequence of the CRT contains several consensus PKC phosphorylation sites (42) . Previous work on transfected oocytes transiently expressing CRT demonstrated a dose-dependent decrease in Cr transport activity in the presence of the PKC activator PMA (9) . In contrast to the observation with Xenopus oocytes, the Cr uptake in Ltk cells transiently expressing a human CRT clone was only slightly inhibited by PMA (42) . Our experiments with giant vesicles from skeletal muscle demonstrated that PMA had no significant effect on Cr transport activity compared with preparations treated with the inactive analog 4␣-phorbol 12,13-didecanoate ( Table 1 ), indicating that, in rat skeletal muscle, CRT activity might be regulated by a different mechanism or, alternatively, that the enzymes involved in this signaling cascade may have been lost during isolation of the giant vesicles.
It has been shown that caffeine supplementation attenuated the ergogenic effect of Cr supplementation in vivo compared with Cr supplementation alone (67) . This has been attributed to increased intramuscular PCr levels. Here, we were able to show that caffeine does not influence CRT function directly, at least in vitro, and that the observed higher PCr levels are rather caused by a shift of the Cr/PCr equilibrium.
Expression of CRT polypeptide species in different tissues. Most tissues in the human organism rely on the uptake of Cr from the extracellular space, especially the metabolically most active tissues with high and fluctuating energy metabolism such as heart, brain, and skeletal muscle, where the highest intracellular Cr concentrations are found (71, 74) . Other tissues, such as kidney, intestine, and lung, contain lower levels of Cr due to their lower and more continuous energy turnover (73) . Nevertheless, these latter tissues still contain millimolar concentrations of Cr and should therefore also express certain amounts of CRT in their plasma membranes. The CRT peptide chain in rat, rabbit, and human contains 635 amino acids (21, 42, 55) , with a calculated molecular mass of 70.6 kDa. Consequently, antisera directed against synthetic peptides corresponding to the NH 2 -and COOH-terminal regions of the polypeptide chain, prepared as described earlier (20) , should recognize a protein of ϳ70 kDa on Western blots. Figure 4A shows an anti-CRT immunoblot where both antisera consistently immunodetected two protein bands with molecular masses of 55 and 70 kDa. In heart and brain, CRT expression seems to correlate roughly with the well documented high total Cr content as well as with the elevated CK activity in these tissues (71, 74) and reflects their increased energetic requirements (72) . In kidney, on the other hand, PCr content and CK activity reach only ϳ5 and 20%, respectively, of those found in brain and muscle (73) . The prominent expression of CRT in kidney might therefore hint at the physiological role of a CRT in kidney that is probably responsible for the recovery of Cr from the urine by the kidney tubules. As expected, lung, testis, and intestine show lower levels of CRT expression. The tissue-specific expression of CRT mRNA by Northern blot hybridization has been investigated previously, and CRT mRNA expression was also detected in most tissues tested but most prominently in kidney, heart, and brain (21, 42, 52, 59) , in agreement with CRT protein expression in these tissues shown in Fig. 4A . In disagreement with the re-sults obtained on immunoblots with anti-CRT antibodies, Northern blots showed that mRNA synthesis is apparently absent in human and rabbit liver (21, 42) . However, experimental evidence for the presence of a CRT in rat liver comes from the fact that perfused liver from transgenic mice, expressing rat cytosolic braintype (B)-CK in this organ, can accumulate intracellular concentrations of Cr and PCr of 25 and 8 mM, respectively, at a Cr concentration of 2 mM in the perfusion medium (6) . This suggests either that a mechanism for the accumulation of Cr also exists in normal liver or that expression of CK and/or accumulation of Cr in transgenic liver are regulatory signals that stimulate expression of a CRT.
Northern blot analysis also demonstrated the differential expression of two CRT mRNAs in various tissues, which was interpreted to arise from alternative polyadenylation (52) or, more likely, arise from differential splicing, as suggested earlier (20) . In agreement with the latter interpretation, our results show the expression of more than one gene product in all tissues tested. Because both the smaller 55-kDa and the 70-kDa CRT proteins share identical NH 2 and COOH termini, they are more likely representing alternatively spliced variants of the CRT, missing one or more of the exons 2 to 12. The existence of a CRT mRNA splice variant missing exon 5 could indeed be confirmed by molecular genetics studies using RACE methods (23) .
A third protein band of 116 kDa is often recognized in heart and, to a lesser extent, in skeletal muscle by both of our anti-CRT antibodies. Because the intensity of this latter band is rather variable, we believe that it might represent a dimer of the 55-and/or 70-kDa polypeptide or that it could be the result of membrane protein aggregation, because its presence was sensitive to the extraction procedure and the detergent used (results not shown).
Differential subcellular localization of CRT polypeptide species. The transport studies with giant sarcolemmal vesicles described here clearly confirm the presence of a specific transport system for Cr in the sarcolemma. Thus CRT protein should be highly enriched in purified plasma membrane vesicles and, as judged from the strong signal of anti-CRT immunoblots in total extracts from skeletal muscle (Fig. 4A) , CRT should be easily detected by anti-CRT antibodies on Western blots. In contrast to our expectations, the immunoreactive signal of the 55-and 70-kDa proteins was almost absent in these highly purified giant sarcolemma vesicle preparations, whereas a rather weak ϳ58-kDa polypeptide appeared that was enriched in these very preparations. Thus, in contrast to the general opinion, the previously identified CRT proteins of 70 and 55 kDa (20, 41, 43, 66) are apparently not plasma membrane proteins. Seemingly, the sarcolemma contains a different CRT species being expressed in only minor amounts corresponding to the relatively low V max value for Cr transport measured.
This result was confirmed by a surface biotinylation study from cardiac myocytes, which also shows a third polypeptide band at ϳ58 kDa that binds to the streptavidin beads and is indeed located in the plasma membrane. Because neither the 55-nor the 70-kDa band was detected in the captured biotinylated protein, we believe that these forms of the protein are not expressed on the surface of cardiac myocytes but instead reside at intracellular locations. This result is in agreement with a recent cell surface biotinylation study on C 2 C 12 myotubes (66) , which, by use of a different CRT antibody, independently detected similar size (ϳ54 and ϳ75 kDa) immunoreactive bands in total muscle cell extracts with a weak intermediary protein band of ϳ58 kDa. In their cell surface biotinylation study, only one band could be enriched in the captured biotinylated proteins, which led the authors of that study to conclude that the other proteins are not expressed on the cell surface, but no conclusions could be given as to their intracellular locations.
Here, we have provided evidence that these proteins are located in mitochondria, since highly purified mitochondria, after density gradient purification, showed an enrichment of the two major CRT species at 55 and 70 kDa. This observation is fully in line with the fact that slow, type I oxidative muscle fibers stained consistently stronger with anti-CRT antibodies compared with fast, type II glycolytic fibers (41) , since the mitochondrial content and volume fraction in type I muscle fibers are significantly higher than in type II muscle fibers and highest in cardiac muscle.
To corroborate this finding, erythrocytes, which have been shown to possess an active Cr transport system (2) but do not contain mitochondria, were probed for CRT expression. We found that mouse erythrocytes express only a single ϳ58-kDa polypeptide form of the CRT, as seen in the captured biotinylated protein and in the plasma membrane vesicles used for transport studies. There is no sign of the existence of polypeptides at 55 or 70 kDa, supporting the hypothesis that the ϳ58-kDa species is an independent plasma membrane-specific form of the CRT and that the major CRT species are located in mitochondria. This latter assumption was clearly confirmed by indirect immunofluorescence labeling of cultured ARC as well as by cross sections of rat soleus, with anti-CRT antibodies that evidently co-localized with the signals of antibodies directed against the mitochondrial marker proteins ANT, VDAC, and COX (Fig. 7, A-H) . We cannot exclude a faint additional plasma membrane staining overlapping with the subsarcolemmal mitochondria, which should arise from the weak ϳ58-kDa immunoreactive CRT band that is visualized by Western blots of highly enriched sarcolemma membranes (Fig. 4B, lane V) . But it becomes clear that the major fraction of the intracellular signal arises from mitochondria, which are the major compartment of CRT protein localization.
It is tempting to speculate whether there is indeed a functional isoform of CRT within mitochondria, and we are presently investigating this question. From recent data obtained with chemically skinned muscle fibers, no additional release of Cr was observed after incubation of such skinned fibers with strong detergents that dissolve mitochondria (40) . These results were taken to indicate that there was no mitochondrial or other membrane-contained Cr compartment. However, it seems entirely conceivable that Cr is lost very quickly from nonenergized mitochondria (76), e.g., during the rather lengthy skinning procedure, and that this would explain why no additional Cr could be released by permeabilizing the mitochondria. In light of the current discussion about a possible intracellular compartmentation of Cr and PCr pools that have been identified by biochemical fractionation studies (58) , by in vivo [
14 C]PCr/Cr isotope tracer measurements (24) , as well as by in vivo nuclear magnetic resonance studies of human skeletal muscle (33) , our data offer an explanation for the existence of a Cr and/or PCr pool in mitochondria that is controlled by mitochondrial CRTs. Thus the exact localization and characterization of these new mitochondrial CRT-related proteins, as well as the regulation of mitochondrial Cr transport, seem to deserve our full attention. This holds especially true with respect to the recently discovered clinical manifestation of a new Cr deficiency syndrome that is based on a genetic defect in CRT (51) .
